Advertisement

Topics

Azacitidine Still Standard of Care in High-Risk MDS

06:23 EDT 22 Aug 2017 | Medscape

A phase 2/3 study compared two combination approaches with azacitidine and concluded that azacitidine alone showed similar efficacy to either combo for patients with high-risk MDS. So what's next in MDS management?
Medscape Medical News

Original Article: Azacitidine Still Standard of Care in High-Risk MDS

NEXT ARTICLE

More From BioPortfolio on "Azacitidine Still Standard of Care in High-Risk MDS"

Advertisement
Quick Search
Advertisement
Advertisement